A study of a blood marker and side effects in advanced breast cancer
Part of Cancer, Skin clinical trials.
This study looks at a protein called GDF-15 in the blood and how it relates to side effects like weight loss during treatment with the drug T-DXd for advanced breast cancer. By joining, you help researchers learn more about managing these side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have breast cancer that is HER2-positive or HER2-low and that has spread or is advanced.
- You are about to start treatment with the drug T-DXd.
- You are not currently receiving nutrition through a feeding tube or IV.
- You are not following a strict low-calorie diet to lose weight.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This trial tests a new drug called Dato-DXd for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to help stop the cancer from growing.
This trial compares a new drug called Trastuzumab-Deruxtecan (T-DXd) to standard treatment for people with early breast cancer whose cancer has come back at a molecular level (detected by a blood test) but hasn't spread to other parts of the body. The goal is to see if T-DXd can prevent the cancer from returning.
This trial tests whether a steroid called dexamethasone, given before T-DXd, can reduce the risk of a rare but serious lung side effect (interstitial lung disease) in people with advanced breast cancer. If it works, it may make treatment safer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.